Mr. Rocca brings over two decades of biotech and diagnostics industry experience, including eleven years of developing and commercializing diagnostic products for autoimmune-related diseases. His prior role was President and CEO of Exagen Inc. (NASDAQ: XGN) which commercialized a suite of testing products enabling healthcare providers to improve care for patients through the differential diagnosis, prognosis and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Prior to Exagen, Mr. Rocca served as Vice President, Sales and Marketing, and as General Manager, at Prometheus Laboratories, Inc., a specialty pharmaceutical and diagnostic company focused on diseases in gastroenterology and oncology. He helped grow the company’s sales to $200 million-plus annually before playing an instrumental role in the $1.4 billion acquisition by Nestlé Health Science S.A. in 2011.
Earlier in his career, Mr. Rocca served in senior sales and marketing management positions for Elan Pharmaceuticals, Inc., a neuroscience-focused biotechnology company. Mr. Rocca received a B.A. in Marketing and Personnel Management from Towson University.
Mr. Rocca also hold two additional Board seats. He is a Board member at Interpace Diagnostics a fully integrated Commercial and bioinformatics company that provides evidence-based, clinically beneficial molecular diagnostic tests and pathology services. And Circular Genomics which is a pioneer in precision medicine, leveraging novel circular RNA biomarkers and bioinformatics.